Integra Lifesciences Holdings Corp (NASDAQ:IART) has been given an average recommendation of “Hold” by the fifteen research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $51.88.
IART has been the subject of a number of analyst reports. Jefferies Group restated a “buy” rating and issued a $56.00 price target on shares of Integra Lifesciences in a research report on Sunday, October 29th. Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research report on Tuesday, October 10th. Oppenheimer restated a “buy” rating and issued a $60.00 price target on shares of Integra Lifesciences in a research report on Monday, September 18th. UBS Group restated a “buy” rating and issued a $57.00 price target on shares of Integra Lifesciences in a research report on Tuesday, October 31st. Finally, TheStreet lowered Integra Lifesciences from a “b” rating to a “c+” rating in a research report on Thursday, October 26th.
Integra Lifesciences (NASDAQ:IART) traded down $0.62 during mid-day trading on Monday, hitting $46.55. The stock had a trading volume of 409,400 shares, compared to its average volume of 479,375. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $3,950.00, a price-to-earnings ratio of 76.31, a PEG ratio of 1.55 and a beta of 0.65. Integra Lifesciences has a 1-year low of $40.51 and a 1-year high of $56.42.
In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barbara B. Hill purchased 10,768 shares of the firm’s stock in a transaction on Tuesday, October 31st. The shares were purchased at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the purchase, the director now directly owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The disclosure for this purchase can be found here. Corporate insiders own 21.50% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in IART. Capital Research Global Investors lifted its stake in Integra Lifesciences by 227.0% during the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock worth $212,441,000 after purchasing an additional 2,705,488 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Integra Lifesciences in the second quarter valued at $112,068,000. Koch Industries Inc. raised its stake in shares of Integra Lifesciences by 12,623.4% in the second quarter. Koch Industries Inc. now owns 754,880 shares of the life sciences company’s stock valued at $741,000 after acquiring an additional 748,947 shares in the last quarter. Orbimed Advisors LLC raised its stake in shares of Integra Lifesciences by 155.5% in the third quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after acquiring an additional 664,000 shares in the last quarter. Finally, FMR LLC raised its stake in shares of Integra Lifesciences by 6.2% in the second quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after acquiring an additional 468,678 shares in the last quarter. Institutional investors own 87.58% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Integra Lifesciences Holdings Corp (IART) Receives Average Rating of “Hold” from Analysts” was originally published by BBNS and is owned by of BBNS. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://baseballnewssource.com/markets/integra-lifesciences-holdings-corp-iart-receives-average-rating-of-hold-from-analysts/1818550.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.